Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune globulin - Evolve Biologics

Drug Profile

Immune globulin - Evolve Biologics

Alternative Names: 10% intravenous immunoglobulin - Evolve Biologics; 10% IVIG - Evolve Biologics; Human Immunoglobulin - Evolve Biologics; Intravenous immunoglobulin - Evolve Biologics; PlasmaCap IG

Latest Information Update: 22 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Therapure Biopharma
  • Developer Evolve Biologics
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Serum globulins; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Immunodeficiency disorders

Most Recent Events

  • 22 Apr 2022 Phase III development in Immunodeficiency disorders is ongoing in USA and Canada (Evolve Biolgics website, April 2022)
  • 23 Feb 2022 Phase III development in Immunodeficiency disorders is ongoing in USA and Canada (Evolve Biolgics website, February 2022)
  • 22 Apr 2021 Evolve Biologics plans regulatory submissions in USA and Canada, in 2025 (Evolve Biolgics website, March,
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top